Why Hims & Hers Health (HIMS) Stock Is Down Today

Hims & Hers Health (HIMS) is down 3.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely explanation is a mix of profit-taking and event-driven caution rather than a single new negative headline. Hims & Hers does not appear to have issued a major adverse announcement today, while investors are heading into the FDA’s July 23-24, 2026 compounding advisory meeting on several peptides, a regulatory event management previously flagged as important for understanding the opportunity ahead. ([investors.hims.com](https://investors.hims.com/news/news-details/2026/Hims--Hers-to-Announce-Second-Quarter-2026-Financial-Results-on-August-10-2026/default.aspx?utm_source=openai))

Details:

The company’s latest investor update, published on July 13, said Hims & Hers will report second-quarter 2026 results on August 10, suggesting there was no obvious fresh earnings shock behind Friday’s move. ([investors.hims.com](https://investors.hims.com/news/news-details/2026/Hims--Hers-to-Announce-Second-Quarter-2026-Financial-Results-on-August-10-2026/default.aspx?utm_source=openai))

The FDA has scheduled a July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting covering multiple peptide-related substances, which keeps regulatory uncertainty in focus for traders. ([fda.gov](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026))

Management said on the first-quarter call that it expected to gain more clarity at the end of July, making the stock especially sensitive to shifting expectations around that timeline. ([s27.q4cdn.com](https://s27.q4cdn.com/787306631/files/doc_financials/2026/q1/Hims-Hers-First-Quarter-2026-Earnings-Call-Transcript-doc.pdf?utm_source=openai))

The backdrop is still mixed: first-quarter revenue rose to about $608 million and subscribers grew to nearly 2.6 million, but gross margin fell to 65% and the company posted a net loss of about $92 million; a late-June filing also disclosed a receivables facility with a $400 million limit. ([investors.hims.com](https://investors.hims.com/news/news-details/2026/Hims--Hers-Health-Inc--Reports-First-Quarter-2026-Financial-Results/default.aspx))

Sources:

Hims & Hers Investor Relations, FDA, SEC ([investors.hims.com](https://investors.hims.com/news/news-details/2026/Hims--Hers-to-Announce-Second-Quarter-2026-Financial-Results-on-August-10-2026/default.aspx?utm_source=openai))

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$HIMS Insider Trading Activity

$HIMS insiders have traded $HIMS stock on the open market 21 times in the past 6 months. Of those trades, 1 have been purchases and 20 have been sales.

Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:

OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 10 sales selling 135,403 shares for an estimated $3,827,101.
MICHAEL CHI (Chief Operating Officer) has made 0 purchases and 2 sales selling 111,316 shares for an estimated $2,843,915.
DAVID B WELLS purchased 48,400 shares for an estimated $1,172,974
MOHAMED ELSHENAWY (CTO) sold 30,040 shares for an estimated $946,260
PATRICK HARRISON CARROLL (Chief Medical Officer) sold 23,726 shares for an estimated $830,410
IRENE BECKLUND (PAO) has made 0 purchases and 3 sales selling 17,592 shares for an estimated $507,029.
SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 3 sales selling 18,926 shares for an estimated $473,439.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive HIMS Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$HIMS Hedge Fund Activity

We have seen 212 institutional investors add shares of $HIMS stock to their portfolio, and 243 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL WORLD INVESTORS removed 14,322,912 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $297,343,653
GOLDMAN SACHS GROUP INC removed 7,892,648 shares (-76.3%) from their portfolio in Q1 2026, for an estimated $163,851,372
DEFIANCE ETFS, LLC added 7,424,258 shares (+inf%) to their portfolio in Q1 2026, for an estimated $154,127,596
MORGAN STANLEY added 4,959,856 shares (+126.2%) to their portfolio in Q1 2026, for an estimated $102,966,610
FARALLON CAPITAL MANAGEMENT LLC removed 3,376,986 shares (-99.7%) from their portfolio in Q1 2026, for an estimated $70,106,229
BANK OF AMERICA CORP /DE/ added 2,877,550 shares (+194.4%) to their portfolio in Q1 2026, for an estimated $59,737,938
RENAISSANCE TECHNOLOGIES LLC removed 2,699,929 shares (-56.0%) from their portfolio in Q1 2026, for an estimated $56,050,526

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$HIMS Price Targets

Multiple analysts have issued price targets for $HIMS recently. We have seen 13 analysts offer price targets for $HIMS in the last 6 months, with a median target of $28.0.

Here are some recent targets:

Allen Lutz from B of A Securities set a target price of $37.0 on 07/09/2026
Maria Ripps from Canaccord Genuity set a target price of $40.0 on 07/01/2026
Glen Santangelo from Barclays set a target price of $39.0 on 06/18/2026
Jailendra Singh from Truist Securities set a target price of $23.0 on 05/22/2026
Ryan MacDonald from Needham set a target price of $35.0 on 05/12/2026
Cory Carpenter from JP Morgan set a target price of $33.0 on 05/12/2026
Daniel Grosslight from Citigroup set a target price of $28.0 on 05/12/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.